[Feasibility and safety of MRgFUS ablation for uterine fibroids and adenomyosis: a preliminary study].

Huang YQ, Y Q Huang, Yaoqu Huang, Shouguo Zhou, Zhou SG, S G Zhou, Juan Wang, J. Wang, Wang J, Deng LX, Lie-xia Deng, L X Deng, Zhenwei Li, Li ZW, Z W Li, Y H Xu, Yihong Xu, Xu YH
Zhonghua yi xue za zhi · 2019 · vol. 99(15) , pp. 1152–1155 · doi:10.3760/cma.j.issn.0376-2491.2019.15.007 · PMID:31006218 · W3003123153
article OA: closed CC0 ⤵ 3 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-08 ⓘ

This preliminary study found MR-guided focused ultrasound surgery to be a safe and effective non-invasive treatment for uterine fibroids and adenomyosis, though adenomyosis treatment requires optimization due to lower ablation efficiency and more adverse reactions.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

MRgFUS is a non-invasive, safe and effective treatment for both uterine fibroids and adenomyosis. Compared with uterine fibroids, MRgFUS treatment of adenomyosis has some disadvantages such as higher energy, lower ablation efficiency and more adverse reactions, and further optimization is needed.

My notes (saved in your browser only)

Condition tags

adenomyosis

MeSH descriptors

Adenomyosis Adenomyosis High-Intensity Focused Ultrasound Ablation Uterine Neoplasms Uterine Neoplasms Adult Female Humans Leiomyoma Magnetic Resonance Imaging Middle Aged Treatment Outcome

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cited by (3)

Cited by (3)

Source provenance

europepmc
last seen: 2026-09-08T06:17:11.951632+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:22:48.502547+00:00
License: CC0 · commercial use OK